New Mexico Entry; Capital Raise
Medicine Man Technologies, Inc. is now operating under its new trade name, Schwazze. Schwazze is executing its strategy to become a leading vertically integrated cannabis holding company with a portfolio consisting of top-tier licensed brands spanning cultivation, extraction, infused-product manufacturing, dispensary operations, consulting, and a nutrient line. Schwazze leadership includes Colorado cannabis leaders with proven expertise in product and business development as well as top-tier executives from Fortune 500 companies. As a leading platform for vertical integration, Schwazze is strengthening the operational efficiency of the cannabis industry in Colorado and beyond, promoting sustainable growth and increased access to capital, while delivering best-quality service and products to the end consumer. The corporate entity continues to be named Medicine Man Technologies, Inc.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Transformational. Friday, Schwazze announced a $95 million capital raise and entry into the New Mexico market. These transactions are transformational for the Company, in our view. The capital from the raise will support Schwazze in achieving its growth target of doubling pro forma revenue by the end of 1Q22, while, with New Mexico, Schwazze is transforming into a super regional from a single state operator.
Capital Raise. Schwazze is raising $95 million ($93 million net) through the sale of convertible notes to institutional investors and individuals. The notes will accrue 13% interest per year (9% payable in cash and 4% accreting to the principal amount) and have a 5-year term. Proceeds from the notes will be used to fund the cash consideration of recently announced acquisitions and other growth and …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.